JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Issues journals
Medical Radiology and Radiation Safety. 2021. Vol. 66. № 5. P. 66–77
Topical Issues of Radiopharmaceuticals Appliance in PET Studies
A.V. Khmelev1,2
1Research Institute – Federal research Center for Project Evaluation and Consulting Services, Moscow, Russia
2Russian Medical Academy of Continuous Professional Education, Moscow, Russiaa
Contact person: Aleksandr Vasilyevich Khmelev: This email address is being protected from spambots. You need JavaScript enabled to view it.
CONTENT
Introduction
1. Requirements to radiopharmaceuticals
2. Factors affecting the biodistribution in organism
3. Uptake and localization mechanisms
4. Appliance in PET studies of biological processes and diagnostics
5. Aspects of regulation of radiopharmaceuticals circulation
Conclusion
Key words: radiopharmaceuticals, radionuclide, localization mechanism, PET
For citation: Khmelev AV. Topical Issues of Radiopharmaceuticals Appliance in PET StudiesSupport of Occupational Radiation Protection during. Medical Radiology and Radiation Safety. 2021;66(5):66-77.
DOI: 10.12737/1024-6177-2021-66-5-66-77
References
1.Vallabhajosula S. Molecular Imaging: Radiopharmaceuticals for PET and SPECT. Berlin, Heidelberg: Springer-Verlag, 2009. 133 p.
2. Saha G.B. Basics of PET Imaging. Physics, Chemistry and Regulation. New York, Springer, 2010. 241 p.
3. Khmelev А.V. Positron Emission Tomography: Physical and Technical Aspects. Мoscow, Trovant Publ., 2016. 336 p. (In Russ.).
4. Zimmermann R.G. Industrial Constraints in the Selection of Radionuclides and the Development of New Radiopharmaceuticals. World J. Nucl. Med. 2008;7:126-34.
5. Qaim M. Development of Cyclotron Radionuclides for Medical Applications: from Fundamental Nuclear Data to Sophisticated Production Technology. In: WTTC15: Proceedings of WTTC15; 2014 Aug 18-21. Prague, Czech Republic Publ., 2014. P. 18-20.
6. Khmelev А.V. Analysis of Positron Emission Tomography Providing with Radionuclides. Medical Radiology and Radiation Safety. 2019;64;6:70-81. (In Russ).
7. Kodina G.E., Krasikova R.N. Methods of Production of Radiopharmaceuticals and Radionuclide Generators for Nuclear Medicine. Мoscow, Izdat. Dom MEI Publ., 2014. 282 p. (In Russ.).
8. Davidson C.D., Phenix C.P., Tai T.C., Khaper N., Lees S.J. Searching for Novel PET Radiotracers: Imaging Cardiac Perfusion, Metabolism and Inflammation. Am. J. Nucl. Med. Mol. Imaging. 2018;8;3:200-27. PMID: 30042871. PMCID: PMC6056242.
9. Wadsak W., Mitterhauser M. Basic and Principles of Pharmaceuticals for PET/CT. E.J.R. 2010;73:461-469. DOI: 10.1016/j.ejrad.2009.12.022. PMID: 20181453.
10. Miller P.W., Long N.J., Vilar R., Gee A.D. Synthesis of 11C, 18F, 15O and 13N Radiolabels for Positron Emission Tomography. Angew. Chem. Int. Ed. 2008;47:8998-9033. DOI: 10.1002/anie.200800222. PMID: 18988199.
11. Zimmermann R.G. Why Are Investors not Interested in My Radiotracer? The Industrial and Regulatory Constraints in the Development of Radiopharmaceuticals. Nucl. Med. Biol. 2013;40:155-166. DOI: 10.1016/j.nucmedbio.2012.10.012. PMID: 23218796.
12. Lau J., Rousseau E., Kwon D., Lin K.-S., Bénard F., Chen X. Insight Into the Development of PET Radiopharmaceuticals for Oncology. Cancers. 2020;12;5:1312-1365. DOI: 10.3390/cancers12051312. PMID: 32455729. PMCID: PMC7281377.
13. Mourtada F., Sims-Mourtada J., Azhdarinia A., Yang D.J. Regulatory Requirements for PET Radiopharmaceuticals Production: Is Automation an Answer? Current Medical Imaging. 2008;4;1:28-33. DOI: 10.2174/157340508783502804.
14. Vallabhajosula S., Killeen R.P. Osborne J.R. Altered Biodistribution of Radiopharmaceuticals: Role of Radiochemical/Pharmaceutical Purity, Physiological, and Pharmacologic Factors. Semin. Nucl. Med. 2010;40:220-241. DOI: 10.1053/j.semnuclmed.2010.02.004 PMID: 20513446.
15. Ziessman H., O'Malley J. Nuclear Medicine: the Requisites. Philadelphia, Saunders, 2014. 464 p.
16. Kamkaew A., Ehlerding E.B., Cai W. Nanoparticles as Radiopharmaceutical Vectors. Radiopharmaceutical Chemistry. Eds. Lewis J., Windhorst A., Zeglis B. New York, Springer, Cham, 2019. P. 181-203.
17. Lee Y.S. Radiopharmaceuticals for Molecular Imaging. The Open Nuclear Medicine Journal. 2010;2:178-185.
18. Jeong J.M. Application of a Small Molecule Radiopharmaceutical Concept to Improve Kinetics. Nucl. Med. Mol. Imaging. 2016;50:99-101. DOI: https://doi.org/10.1007/s13139-015-0369-6.
19. Waterhouse R.N. Determination of Lipophilicity and Its Use as a Predictor of Blood-Brain Barrier Penetration of Molecular Imaging Agents. Mol. Imaging. Biol. 2003;5;6: 376-89. DOI: 10.1016/j.mibio. 2003.09.014 PMID: 14667492.
20. Silindir M., Özer A.Y. Recently Developed Radiopharmaceuticals for Positron Emission Tomography (PET). Fabad. J. Pharm. Sci. 2008;33:153-62.
21. Colom M., Vidal B., Zimmer L. Is there a Role for GPCR Agonist Radiotracers in PET Neuroimaging? Front. Mol. Neurosci. 2019;12:255-94. DOI: 10.3389/fnmol.2019.00255. PMID: 31680859. PMCID: PMC6813225.
22. Komal S., Nadeem S., Faheem Z., Raza A., Sarwer K., Umer H., et al. Localization Mechanisms of Radiopharmaceuticals. 2020. Available from: https://www.intechopen.com/online-first/localization-mechanisms-of-radiopharmaceuticals. DOI:10.5772/intechopen.94099.
23. Ponto J.A. Mechanisms of Radiopharmaceutical Localization. Ed. Norenberg J. UNM Сollege of pharmacy. 2012;16;4:2-35.
24. Lim M.M.D., Gnerre J., Gerard P. Mechanisms of Uptake of Common Radiopharmaceuticals. RadioGraphics Fundamentals |Online Presentation. Radiographics. 2018;38;5:1550-51. Available from: https://doi.org/10.1148/rg.2018180072
25. Kilian K. 68Ga-DOTA and Analogs: Current Status and Future Perspectives. Rep. Pract. Oncol. Radiother. 2014;19:13-21. DOI: 10.1016/j.rpor.2014.04.016. PMID: 28443194.
26. Huang Y.Y. An Overview of PET Radiopharmaceuticals in Clinical Use: Regulatory, Quality and Pharmacopeia Monographs of the United States and Europe. 2018. Available from: https:// www.intechopen.com /books/nuclear-medicine-physics/an-overview-of-pet-radio pharmaceuticals-in-clinical-use-regulatory-quality-and-pharmacopeia-monograp. DOI:10.5772/intechopen.79227.
27. Perk L.R., Stigter-van Walsum M., Visser G.W., Kloet R.W., Vosjan M.J.W.D., Leemans C.R., et al. Quantitative PET Imaging of Met-Expressing Human Cancer Xenografts with 89Zr-Labelled Monoclonal Antibody DN30. Eur. J. Nucl. Med. Mol. Imaging. 2008;35:1857-1867. Available from: https://doi.org/10.1007/s00259-008-0774-5.
28. Brooks A.F., Drake L.R., Stewart M.N., Cary B.P., Jackson I.M., Mallette D., et al. Fluorine-18 Patents (2009–2015). Part 1. Novel Radiotracers. Pharm. Pat. Anal. 2016;5;1:17-47. DOI: 10.4155/ppa.15.36. PMID: 26670619. PMCID: PMC5561792.
29. Pagani M., Stone-Elander S., Larsson S.A. Alternative Positron Emission Tomography with Non-Conventional Positron Emitters: Effects of Their Physical Properties on Image Quality and Potential Clinical Applications. Eur. J. Nucl. Med. 1997;24;10:1301-1327. DOI: 10.1007/s00259 0050156. PMID: 9323273.
30. Jødal L., Le Loirec С., Champion С. Positron Range in PET Imaging: Non-Conventional Isotopes. Physics in Medicine and Biology. IOP Publishing. 2014;59:7419-34. Available from: https://www.hal.archives-ouvertes.fr/hal-01174227.
31. Jung J., Ahn B.-C. Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors. Brain Tumor Res Treat. 2018;6;2:47-53. DOI: 10.14791/btrt.2018.6.e13.PMID: 30381916. PMCID: PMC62 12689.
32. Zykov E.M., Pozdnyakov A.V., Kostenikov N.A. Efficient Use of PET and PET/CT in Oncology. Practical Oncology. 2014;15;1:31-6 (In Russ.).
33. Lopci E., Grassi I., Chiti A., Nanni C., Cicoria G., Toschi L., et al. PET Radiopharmaceuticals for Imaging of Tumor Hypoxia: a Review of the Evidence. Am. J. Nucl. Med. Mol. Imaging. 2014;4;4:365-384. PMID: 24982822. MCID: PMC4074502.
34. Andersson J.D., Halldin C. PET Radioligands Targeting the Brain GABAA/Benzodiazepine Receptor Complex. J. Label. Compd. Radiopharm. 2013;56:196-206. DOI: 10.1002/jlcr.3008. PMID: 24285326.
35. Meisenheimer M., Saenko Yu., Eppard E. Gallium-68: Radiolabeling of Radiopharmaceuticals for PET Imaging- a Lot to Consider. 2019. Available from: https://www.intechopen.com/books/medical- isotopes/gallium-68-radiolabeling-of-radiopharmaceuticals-for-pet-imaging-a-lot-to-consider. IntechOpen. DOI: 10.5772/intechopen.90615.
36. Weineisen M., Schottelius M., Simecek J., Baum R.P., Yildiz .A., Beykan S., et al. 68Ga- and 177Lu-labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J. Nucl. Med. 2015;56;8:1169-1176. PMID: 26089548. DOI: 10.2967/jnumed.115.158550.
37. Werner R.A., Bluemel C., Allen-Auerbach M.S., Higuchi T., Hermann R. 68Gallium- and 90Yttrium-/ 177Lutetium: “Theranostic Twins” for Diagnosis and Treatment of NETs. Ann. Nucl. Med. 2015;29:1-7. DOI: https://doi.org/10.1007/s12149-014-0898-6.
38. van de Watering F.C.J., Rijpkema M., Perk L., Brinkmann U., Oyen W.J.G., Boerman O.C., et al. Zirconium-89 Labeled Antibodies: a New Tool for Molecular Imaging in Cancer Patients. Biomed. Res. Int. 2014;2014;203601. DOI: 10.1155/2014/203601. PMID: 24991539.
39. Dijkers E.C., Kosterink J.G., Rademaker A.P., Perk L.R., van Dongen G.A.M.S., Bart J., et al. Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/New ImmunoPET Imaging. J. Nucl. Med. 2009 50:974-981. PMID: 19443585 DOI: 10.2967/jnumed.108. 060392.
40. Mahajan S., Divgi C.R. The Role of Iodine-124 Positron Emission Tomography In Molecular Imaging. Clin Transl Imaging. 2016;4;4:297-306. PMID: 27158012. DOI: 10.1016/j.cpet.2008.05.001.
41. FDA-Approved Radiopharmaceutical. Cardinal Health. 2019. Rev. 21/6.26.20. Available from: https://www.cardinalhealth.com/content/ dam/corp/web/documents/fact-sheet/cardinal-health-fda-approved-radiopharmaceuticals.pdf.
42. Clarke B.N. PET Radiopharmaceuticals: what’s New, what’s Reimbursed, what’s Next? J. Nucl. Med. Tech. 2018;46;1:12-16. PMID: 29438008. DOI: 10.2967/jnmt.117.205021.
43. Zelinskaya E. Radiopharmacy – Unique Trending of Pharmaceutic Industry. GMP News. 2018;2;16:55-70 (In Russian).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The author declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors
Article received: 23.12.2020.
Accepted for publication: 20.01.2021.
Medical Radiology and Radiation Safety. 2021. Vol. 66. № 5. P. 78–84
Morbidity of Children's Population of Lermontov City, Located in the Uranium Legacy Area
Lyaginskaya A.M., Shandala N.K., Titov A.V., Metlyaev E.G., Kuptsov V.V., Karelina N.M.
A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: YEvgeny Georgievich Metlyaev: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To carry out assessment the health status of the child population of the Lermontov city. This child population living in the area, of uranium legacy, and they are critical group of the population in terms of sensitivity to adverse environmental factors.
Materials and methods: The object of the study was the morbidity of children 0–14 years old (primary, chronic, oncological). The research material was the data of reporting forms of medical statistics, presented in the following forms: 7 – information on malignant neoplasms and 12 - information on the number of diseases in children. The development included data from Clinical hospital # 101 of the FMBA of Russia for 2014–2018. Statistical data processing was carried out using standard methods used for the analysis of biomedical data.
Results: The morbidity of children 0–14 years old in Lermontov in 2014–2018 averaged 2310.9 ± 115.7 per 1000. In the structure of morbidity, the leading places were occupied by diseases of the respiratory system – 59.2 %, the digestive system – 8.8 %, skin and subcutaneous tissue 5.5 %, trauma and poisoning – 4, 8 % and infectious and parasitic diseases. The frequency of chronic morbidity does not exceed the population estimates – 73.0 ± 4.1 per 1000. The peculiarity of chronic morbidity is the relatively high incidence of skin diseases – 25.3 % and the musculoskeletal system – 20.4 %. The morbidity of children in the first year of life is 2348.0 ± 135.1 per 1000. A feature of the morbidity structure is the high incidence of respiratory diseases, which makes up 66.3 % of the total morbidity, with population estimates – 20–30 %.
Conclusion: The increased radiation background can be considered as one of the possible negative environmental factors affecting the health of the population.
Key words: morbidity, childhood, uranium legacy sites, critical population group, radon progeny
For citation: Lyaginskaya AM, Shandala NK, Titov AV, Metlyaev EG, Kuptsov VV, Karelina NM. Morbidity of Children's Population of Lermontov City, located in the Uranium legacy Area. Medical Radiology and Radiation Safety. 2021;66(5):78-84.
DOI: 10.12737/1024-6177-2021-66-5-78-84
References
1. Material from the free online encyclopedia - Wikipedia. Available at: https://ru.wikipedia.org/wiki/Лермонтов_(город) (Accessed 01 July 2020) (In Russian).
2. Titov AV, Shandala NK, Marenny AM et al. The radiation situation at the facility of the former LPO Almaz enterprise. Hygiene and Sanitation 2017; 96 (9); P. 822-826. (In Russian).
3. Assessment of the radioecological situation and environmental quality management in the regions where typical enterprises of the industry are located. Volume 1. Assessment of the radioecological situation and environmental quality management at the State Unitary Enterprise "Hydrometallurgical Plant" (HMP). M., 2001. (In Russian).
4. Titov AV, Shandala NK, Isaev DV, Semenova МP, Seregin VА, Belskikh YuS, Ostapchuk TV, Chernobaev AS. Assessment of the Public Radiation Protection and Economic Activity Safety in the Area of the Developed Uranium Deposit. Medical Radiology and Radiation Safety. 2020;65(2):11-16. (In Russian)
5. Report «On the state of sanitary and epidemiological well-being of the population in the city of Lermontov, Stavropol Territory in 2017». Analysis of activities for the section of work - radiation safety and occupational health for 2017. http://mru101 .fmbaros.ru/deyatelnost/sanitarno-epidemiologicheskoe-sostoyanie/ (Accessed 07 January 2020). (In Russian)
6. Marenny AM, Romanov VV, Astafurov VI, Gubin AT, Kiselev SM, Nefedov NA, Penezev AV. Carrying out surveys of buildings for various purposes for radon content in the territories served by FMBA of Russia. // Radiation Hygiene. 2015; 8 (1): 23-29.
7. ICRP, 2007. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Ann. ICRP 37 (2-4).
8. ICRP, 2014. Radiological Protection against Radon Exposure. ICRP Publication 126. Ann. ICRP 43(3).
9. ICRP, 2010. Lung Cancer Risk from Radon and Progeny and Statement on Radon. ICRP Publication 115, Ann. ICRP 40(1).
10. Merkov AM, Polyakov LE Guide for doctors. Sanitary statistic. “Medicine” Moscow, 1974.–384 p. (In Russian)
11. Unified system of control and accounting of individual radiation doses to citizens (ESKIF). Federal database of individual radiation doses for personnel of organizations and the population in the territories served by the FMBA of Russia and the Ministry of Defense of Russia. – М., 2012 – 86 p.
12. Merabishvili VM, Dyatchenko OT Dynamics of oncological morbidity and mortality in children (0–14) in St. Petersburg. J. Oncology Issues 2008 Vol.54 p. 272-280. (In Russian)
13. Schepin OP, Korotkikh RV, Schepin VO, Medic VA Public health is the foundation of health development; under the editorship of Schepin OP. – М., National Research Institute of Public Health, Russian Academy of Medical Sciences, 2009. – 376 p. (In Russian)
14. Ulumbekova GE Health care in Russia. Results of 2012-2016. Urgent measures in 2017-2018. Priorities of development until 2025. – М., ed. Group «GEOTAR-Media», 2017. 47 p. (In Russian)
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution.
Research concept and design – Lyaginskaya A.M., Shandala N.K .., Titov A.V .;
Collection and processing of material – Lyaginskaya A.M., Shandala N.K .., Titov A.V., Metlyaev E.G .;
Text writing – V.V. Kuptsov Karelina N. M .;
Editing – Lyaginskaya A.M., Shandala N.K . Titov A.V.;
Approval of the final version of the article, responsibility for the integrity of all parts of the article – all co-authors
Article received: 16.03.2021.
Accepted for publication: 21.04.2021.
Medical Radiology and Radiation Safety. 2021. Vol. 66. № 5. P. 91–94
Incidence of Basal Cell Carcinoma in Cohort of Mayak Workers
M.V. Bannikova, T.V. Azizova
Southern Urals Biophysics Institute, Ozyorsk, Chelyabinsk region, Russia
Contact person: TamaraVasil’evna Azizova: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Results: To estimate incidence rates for basal cell carcinoma (BSC) following chronic occupational radiation exposure.
Conclusion:The study cohort included 22,377 workers (25.4 % of females) of the nuclear production facility, Mayak Production Association (PA), who had been hired in 1948–1982. Gamma doses of external exposure were provided by the Mayak Workers Dosimetry System – 2013 (MWDS–2013). The cohort was followed up until 31.12.2018.
Results: By the end of the follow-up period 293 BSC cases were registered in the study cohort. BSC incidence rates significantly increased with increasing attained age of workers. The highest BSC incidence rate was observed in the age group above 70 years, both for males and females. The study found a significant increasing linear trend for standardized incidence rates for both males and females; approximation confidence factors were R2 = 0.82 and R2 = 0.95, respectively. The majority of BSC cases in the study cohort were registered in 1994–2018 (71.12 % in males and 81.13 % in females). The component analysis demonstrated that the absolute growth in the BSC incidence rate in both males and females was due to changes in the age structure of the study population and the risk of the disease.
Conclussion: BSC incidence rates were significantly higher in males externally exposed to gamma rays at cumulative skin absorbed doses 0.2–0.5 Gy, 0.5–1.0 Gy and above 1.0 Gy compared to those exposed at doses below 0.1 Gy. In females the corresponding differences were non-significant.
Key words: basal cell carcinoma, incidence rates, ionizing radiation, Mayak
For citation: Bannikova MV, Azizova TV. Incidence of Basal Cell Carcinoma in Cohort of Mayak Workers. Medical Radiology and Radiation Safety 2021;66(5):91-94.
DOI: 10.12737/1024-6177-2021-66-5-91-94
References
1. World Health Organization. International Statistical Classification of Disease and Related Health Problems, Tenth Revision (ICD-10) Geneva: World Health Organization; 1992.
2. Rybkina VL, Azizova TV, Adamova GV. Risk factors of malignant neoplasms of the skin. Epidemiology. Clinical dermatology and venereology. 2019;18;5:548-555 (In Russian).
3. Kaprin AD, Starinskiy VV, Shahzadova AO. Malignant neoplasms in Russia (incidence and mortality). National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation. Moscow Publ., 2020. 252 p. (In Russian).
4. Napier BA. The Mayak Worker Dosimetry System (Mwds–2013): an Introduction to the Documentation. Radiat Prot Dosimetry. 2017;176;1–2:6–9. DOI: 10.1093/rpd/ncx020.
5. Glantz SA. Primer of biostatistics. Fourth edition, Moscow, Practika Publ.; 1999.
6. Merkov AM, Polyakov LE. Health Statistics (Manual for Doctors). Moscow, Medicine Publ., 1974 (In Russian).
7. Chisov BI. Organization of Oncological Service in Russia. Guidelines, Manual for Doctors. Part 2. Moscow Publ., 2007. P. 130-136 (In Russian).
8. Shlyahtunov EA. Skin Cancer: Current State of the Problem. Vestnik VGMU, 2014;13;3 (In Russian).
9. Ufimtseva MA, Lipatov GYa, Shubina AS, Petkau VV, Beresneva TA. Epidemiological aspects of malignant skin neoplasms morbidity in Sverdlovsk region. Human ecology, 2020. 03. DOI: 1033396 / 1728-0869-2020-3-4-9.
10. Azizova TV, Bannikova MV, Grigoryeva ES, Rybkina VL. Risk of Malignant Skin Neoplasms in a Cohort of Workers Occupationally Exposed to Ionizing Radiation at Low Dose Rates. PLoS ONE; 2018;13;10:e0205060. https ://doi.org/10.1371/journ al.pone.02050 60.
11. Azizova TV, Bannikova MV, Grigoryeva ES, Rybkina1 VL. Risk of Skin Cancer by Histological Type in A Cohort of Workers Chronically Exposed to Ionizing Radiation. Radiation and environmental biophysics. 2021;60:9–22 https://doi.org/10.1007/s00411-020-00883-6.
12. Decree of the Ministry of Health of the Russian Federation as of 28.01.2021 No.29n on the approval of the procedure for mandatory preliminary and periodic medical examinations of workers provided for in article 213, paragraph 4, of the Labour Code, the list of medical contraindications for occupational activities with harmful and (or) hazardous industrial factors and such activities that require mandatory and routine medical examinations. (In Russian).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 23.12.2020.
Accepted for publication: 20.01.2021.
Medical Radiology and Radiation Safety. 2021. Vol. 66. № 5. P. 85–90
Cancer Registry of Population in the City Ozyorsk:
Structure of Malignant Neoplasms First Diagnosed in Period From 1948 to 2016
P.V. Okatenko1, E.P. Fomin2, E.V. Denisova1, I.S. Kuznetsova1, M.E. Sokolnikov1, N.A. Koshurnikova1
1 Southern Urals Biophysics Institute FMBA, Ozyorsk, Russia
2 Clinical Hospital №71 FMBA, Ozyorsk, Russia
Contact person: Pavel Viktorovich Okatenko: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: The analysis of the structure of malignant neoplasms (MN) incidence among the population in the city Ozyorsk, located near Mayak Production Association, based on the information from the territorial cancer registry.
Materials and methods: There were 14681 first diagnosed cases of malignant neoplasms at the period from 1948 to 2016 in the territorial cancer registry of Ozyorsk. The diagnoses were verified by all available medical documents.
The structure of MN incidence, vital status of diseased people, age in a year of diagnostics, rank distribution of the basic localizations were studied.
Results: For 70 years period of follow-up there were 7676 cases from 14681 of MN incidence cases during the last 17 years (from 2000 to 2017) – as much as for the previous 51 years of follow-up from 1948 to 1999 (7005 cases). In the MN structure solid cancer constitutes 94.5 %, hemoblastoses – 5.5 %. As at December 31, 2016 23.3 % of the diseased people were alive, 75.2 % died from all causes, 1.5 % lost to follow-up. The cause of 80,6 % deaths was MN. Age in the year of diagnostics constitutes 61,7 years. 75.8 % diagnoses have morphological confirmation. During the entire period of follow-up first three places belong to lung cancer, gastric cancer and prostate cancer for males; breast cancer, gastric cancer and colon cancer for females in the MN structure.
Conclusions: During the period from 1948 to 2016 the growth of the first diagnosed MN cases among the population of Ozyorsk was a result of the population doubling and a fourfold increase of the citizens over the age of 50. Developed and supported cancer registry allows to analyze and partially control oncological situation in the closed cities of Rosatom.
Key words: cancer-registry, Mayak PA, Ozyorsk, population, malignant neoplasm
For citation: Okatenko PV, Fomin EP, Denisova EV, Kuznetsova IS, Sokolnikov ME, Koshurnikova NA. Cancer Registry of Population in the City Ozyorsk: Structure of Malignant Neoplasms First Diagnosed in Period From 1948 to 2016. Medical Radiology and Radiation Safety. 2021;66(5):85-90.
DOI: 10.12737/1024-6177-2021-66-5-85-90
References
1. A Review of Human Carcinogens. Part D: Radiation. Lyon, France, IARC, 2012. 363 p.
2. Ed. Kiselev M.F., Shandala N.K. ICRP Publication 103. Moscow, Alana Publ., 2009. 344 p. (In Russ.).
3. Vazhenin A.V., Domozhirova A.S., Aksenova I.A., et al. Epidemiological Peculiarities of the Oncological Situation and Health Status Indicators of the Oncological Care Among the Population of Chelyabinsk Region in 2018. Chelyabinsk Publ., 2018. 60 p. (In Russ.).
4. Cancer Registration: Principles and Methods. Lyon, France, IARC, 1991. 169 p.
5. Zielinski J.M., Shilnikova N.S., Krewski D. Canadian National Dose Registry of Radiation Workers: Overview of Research from 1951 through 2007. Int. J. Occup. Med. Environ Health. 2008;21;4:269-75.
6. Haylock R.G.E., Gillies M., Hunter N., et al. Cancer Mortality and Incidence Following External Occupational Radiation Exposure: an Update of the 3rd Analysis of the UK National Registry for Radiation Workers. British Journal of Cancer. 2018;119:631–637.
7. Hunter N., Harrison J.D., Kuznetsova I.S., Labutina E.V. Solid Cancer Incidence other than Lung, Liver and Bone in Mayak Workers: 1948-2004. Br. J. Cancer. 2013;109;7:1989-1996.
8. Labutina E.V., Kuznetsova I.S., Hunter N., et al. Radiation Risk of Malignant Neoplasms in Organs of Main Deposition for Plutonium in the Cohort of Mayak Workers with Regard to Histological Types. Health Phys. 2013;105;2:165-76.
9. Kuznetsova I.S., Labutina E.V., Hunter N. Radiation Risks of Leukemia, Lymphoma and Multiple Myeloma Incidence in the Mayak Cohort: 1948-2004. PLoS ONE. 2016;11;9:1-14.
10. Novoselov V.N., Nosach Yu.F., Entyakov B.N. Atomic Heart of Russia. Chelyabinsk, Avtograf Publ., 2014. 528 p. (In Russ.).
11. Fomin E.P., Okatenko P.V., Koshurnikova N.A. Malignant Neoplasms Incidence among Ozersk Population During the Period 1948-2005. Medical Radiology and Radiation Safety. 2007;52;6:29-34 (In Russ.).
12. Tretyakov F.D., Romanov S.A., Prishchepova M.S., Ryzhov V.P. Demographic Situation in the City Ozersk. Ozersk Publ., 2007. 32 p. (In Russ.).
13. Malignant Neoplasms in Russia. http://www.oncology.ru/service/statistics/malignant_tumors/ (In Russ.).
14. Merkov A.M., Polyakov L.E. Sanitary Statistics. Moscow, Meditcine Publ., 1974. 384 p. (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 23.12.2020.
Accepted for publication: 20.01.2021.
Medical Radiology and Radiation Safety. 2021. Vol. 66. № 5. P. 95–100
Estimation of Radiotherapy Efficiency of Head-and-Neck Cancer Based on Tumor Control Probability Model
Е.S. Sukhikh1,2, L.G. Sukhikh 2, Ya.N. Sutygina1,2, P.V. Izhevsky3, I.N. Sheino3, O.M.Stakhova2,4, M.I. Klinovitskaya2
1Tomsk Regional Oncology Center, Tomsk, Russia
2National Research Tomsk Polytechnic University, Tomsk, Russia
3 A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
4Multidisciplinary Clinical Medical Ccenter “Medical city”, Tyumen, Russia
Contact person: Olga Mikhailovna Stakhova: This email address is being protected from spambots. You need JavaScript enabled to view it. .
ABSTRACT
Purpose: Evaluation of the expected effectiveness of radiation therapy based on models of the local tumor control probability (Tumor Control Probability – TCP) for the head-neck cancer.
Material and мethods: The study used data from 11 patients with locally advanced head-neck cancer (larynx, oropharynx, and oral cavity). For each patient two dosimetric treatment plans have been prepared: SIB-VMAT (70 Gy per tumor, 50 Gy per lymph nodes, 25 fractions) and SEQ-VMAT (70 Gy per tumor, 50 Gy per lymph nodes, 35 fractions). The developed plans were analyzed using A. Niemierko's TCP model with parameters obtained by B. Maciejewski (TCD50 = 70.26 Gy with a 49-day total treatment time), taking into account the dose–volume histograms and the total treatment time.
Results: The developed plans ensured a high level of coverage (98–98 %) of the Clinical treatment volume (CTV) in all but one patient. The average TCP SIB-VMAT is 99.9 % due to the very short total treatment time. The average TCP for SEQ-VMAT is 61.0%. For one patient, both SIB-VMAT and SEQ-VMAT showed zero expected efficacy due to 95–95 % CTV coverage.
Conclusion: The use of TCP model allows analyzing personalized treatment plans for patients and developing adaptive treatment regimens with an increase in the total dose, dose per fraction, and a decrease in the total treatment time.
Key words: locally advanced cancer head and neck, volumetric modulated arc therapy, simultaneous integrated dose escalation, tumor control probability, TCP model
For citation: Sukhikh ЕS, Sukhikh LG, Sutygina YaN, Izhevsky PV, Sheino IN, Stakhova OM, Klinovitskaya MI. Estimation of Radiotherapy Efficiency of Head-and-Neck Cancer Based on Tumor Control Probability Model. Medical Radiology and Radiation Safety 2021;66(5):95-100.
DOI: 10.12737/1024-6177-2021-66-5-95-100
References
1. Каприн А.Д, Старинский В.В, Петрова Г.В. Злокачественные новообразования в России в 2017 году. Заболеваемость и смертность. 2018. Available from: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.
2. Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, et al. Final Results of Local-Regional Control and Late Toxicity of RTOG 9003: A Randomized Trial of Altered Fractionation Radiation for Locally Advanced Head and Neck Cancer // International Journal of Radiation Oncology Biology Physics. 2014. V.89, No. 1. P. 13–20. DOI: 10.1016/j.ijrobp.2013.12.027. PMID: 24613816.
3. Dragan T., Beauvois S, Moreau M, Paesmans M, Vandekerkhove C, Cordier L, et al. Clinical Outcome and Toxicity after Simultaneous Integrated Boost IMRT in Head and Neck Squamous Cell Cancer Patients // Oral Oncology. 2019. No. 98. P. 132–140. DOI: 10.1016/j.oraloncology.2019.09.012. DOI: 10.1016/j.oraloncology.2019.09.012. PMID: 31586895.
4. Maciejewski B, Withers HR, Taylor JMG, Hliniak A. Dose Fractionation and Regeneration in Radiotherapy for Cancer of the Oral Cavity and Oropharynx: Tumor Dose-Response and Repopulation // International Journal of Radiation Oncology, Biology, Physics. 1989. V.16, No. 3. P. 831–843. DOI: 10.1016/0360-3016(89)90503-8. PMID: 2921175.
5. Orlandi E, Palazzi M, Pignoli E, Fallai C, Giostra A, Olmi P. Radiobiological Basis and Clinical Results of the Simultaneous Integrated Boost (SIB) in Intensity Modulated Radiotherapy (IMRT) for Head and Neck Cancer: A Review // Critical Reviews in Oncology/Hematology. 2010. V.73, No. 2. P. 111–125. DOI: 10.1016/j.critrevonc.2009.03.003. PMID: 19409808.
6. Chao KSC, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of Failure in Patients Receiving Definitive and Postoperative IMRT for Head-and-Neck Cancer // International Journal of Radiation Oncology Biology Physics. 2003. V.55, No. 2. P. 312–321. DOI: 10.1016/s0360 -3016(02)03940-8. PMID: 12527043.
7. Spiotto MT, Weichselbaum RR Comparison of 3D Confromal Radiotherapy and Intensity Modulated Radiotherapy with or Without Simultaneous Integrated Boost During Concurrent Chemoradiation for Locally Advanced Head and Neck Cancers // PLoS ONE. 2014. V.9, No. 4. DOI: 10.1371/journal.pone.0094456. PMID: 24714187.
8. Vlacich G, Stavas MJ, Pendyala P, Chen SC, Shyr Y, Cmelak AJ. A Comparative Analysis Between Sequential Boost and Integrated Boost Intensity-Modulated Radiation Therapy with Concurrent Chemotherapy for Locally-Advanced Head and Neck Cancer // Radiation Oncology. 2017. V.12, No. 1. DOI: 10.1186/s13014-016-0756-x. PMID: 28086954.
9. Vanasek J, Odrazka K, Dusek L, Jarkovsky J, Michalek R, Chrobok V, et al. Experience with Intensity-Modulated Radiotherapy in the Treatment of Head and Neck Cancer // Journal of BUON. 2013. V.18, No. 4. P. 970–976. PMID: 24344025.
10. Farrag A, Voordeckers M, Tournel K, De Coninck P, Storme G. Pattern of Failure after Helical Tomotherapy in Head and Neck Cancer // Strahlentherapie und Onkologie. 2010. V.186, No. 9. P. 511–516. DOI: 10.1007/s00066-010-2130-5. PMID: 20803182.
11. Barry MA, Hussein M, Schettino G. Evaluating the Propagation of Uncertainties in Biologically Based Treatment Planning Parameters // Front. Oncol. 2020. DOI: 10.3389/fonc.2020.01058. PMID: 32793468.
12. Niemierko A. Reporting and Analyzing Dose Distributions: A Concept of Equivalent Uniform Dose // Medical Physics. 1997. V.24, No. 1. P. 103–110. DOI: 10.1118/1.598063. PMID: 9029544.
13. Gay HA., Niemierko A A. Free Program for Calculating EUD-Based NTCP and TCP in External Beam Radiotherapy // Physica Medica. 2007. No. 3-4. P. 115–125. DOI: 10.1016/j.ejmp.2007.07.001. PMID: 17825595.
14. Bigelow EO, Seiwert TY, Fakhry C. Deintensification of Treatment for Human Papillomavirus-Related Oropharyngeal Cancer: Current State and Future Directions // Oral Oncology. 2020. No. 105. DOI: 10.1016/j.oraloncology.2020.104652. PMID: 32247987.
15. Fakhry C, Zhang Q, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Weber RS, et al. Validation of NRG Oncology/RTOG-0129 Risk Groups for HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Cancer: Implications for Risk-Based Therapeutic Intensity Trials // Cancer. 2019. V.125, No. 12. P. 2027–2038. DOI: 10.1002/cncr.32025. PMID: 30913305.
16. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five Compared with Six Fractions Per Week of Conventional Radiotherapy of Squamous-Cell Carcinoma of Head and Neck: DAHANCA 6&7 Randomised Controlled Trial // Lancet. 2003. V.362, No. 9388. P. 933–940. DOI: 10.1016/s0140-6736(03)14361-9. PMID: 14511925.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 23.12.2020.
Accepted for publication: 20.01.2021.